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The biomonitoring of the 
hepatotoxic effects are 
conducted by evaluating the 
biochemical markers, mainly 
liver enzymes (serum 
transferases) as important 
indicators or parameters for 
evaluating the hepatotoxic 
effect of certain chemical 
agents, in our study,  statins. 
Recruitment and diagnostic 
tests were conducted in the 
University Clinic of Clinical 
Chemistry,Clinical Center 
“Mother Teresa” in Skopje. The 
study was performed in the 
years 2017-2018
Dyslipidemia in the subjects is define with observation of complete lipid status
including total cholesterol (TC) (the mean=5.68mmol/L), low-density lipoprotein cholesterol
(LDL-C) (the mean=2.49 mmol/L), triglycerides (TG)(the mean= 3.22mmol/L) and highdensity
lipoprotein cholesterol (HDL-C) (the mean=1.24mmol/L).
All of the subjects used the herapy with statins (atorvastatin and rosuvastatin) for 
minimum of 6 months with daily dose of statins 5-40 mg.
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The observation of total serum transferases confirmed that 20 of the subjects (71,42%) 
have a normal serum trasferases (AST and ALT) but 8 of the subjects (28,58%) have a 
abnormal level of serum trasferases
 
Liver 
enzymes 
Group -1 
(Atorvastatin) 
Group -2 
(Rosuvastatin)  
Total  
 N % N N N % 
Normal  10 66.7 10 76,92% 20 71,42% 
Abnormal  5 33.3 3 23,18% 8 28,58% 
Total  15 100 13 100 28 100 
No. of subjects 
with 
atorvastatin 
therapy 
(normal level of 
serum 
transferases) 
 
 
 
AST 
 
 
 
 
ALT 
 
No. of 
subjects with 
rosuvastatin 
therapy 
(normal level 
of serum 
transferases) 
 
 
 
AST 
 
 
 
 
ALT 
 
1.  22 15 1.  17 20 
2.           16 16 2.  31 49 
3.  21 18 3.  16 17 
4.  21 22 4.  28 24 
5.  17 12 5.  21 14 
6.  
16 22 6.  23 15 
7.  
28 40 7.  28 24 
8.  
19 14 8.  21 20 
9.  
27 31 9.  22 13 
10.  
18 33 10.  22 16 
Mean  S.D. 20.5 4.2 22.3 9.4 Mean  S.D. 22.9 4.8 21.2 10.5 
 
Table 2. Number of subjects with  atorvastatin and rosuvastatin therapy with 
normal level of AST and ALT
 (GROUPE 1) 
No. of 
subjects with 
atorvastatin 
therapy 
(abnormal 
level of serum 
transferases) 
 
AST 
(10-34) 
U/L 
ALT  
(10-45) 
U/L 
 
(GROUPE 
2) 
No. of 
subjects 
with 
rosuvastatin 
therapy 
(>10 time of 
level of 
serum 
transferases) 
AST U/L 
10-34 
ALT U/L 
10-45 
1 47 87 1 700 4319 
2 38 69 2 154 93 
3 49 112 3 887 995 
4 44 50    
5 40 50    
 
meanS.D. 
 
43.64.6 73.626.4 
 
meanS.D. 
 
580.3380.9 1802.32225.7 
 
Table 3. Number of subjects with  atorvastatin and rosuvastatin therapy with 
abnormal level of AST and ALT
Table 1. The total number and percentage of subject with normal and abnormal level of 
serum transferases
The doses of statins should be adjusted 
and monitored more responsible. 
Monitoring of
liver enzymes should be done before the 
start of treatment with statins
During treatment, the focus should be 
done not only on clinical symptoms 
Statins therapy (on patients with 
dyslipidemia) combined with other 
metabolic drugs and inhibitors, might 
increase the risk of liver injury
Individual
differences, such as sex, age, sensitivity 
and immune ability, affect the degree of 
hepatotoxicity
With results of our study we want to emphasize 
the importance of biomonitoring of liver 
enzymes as biomarkers which associated 
hepatotoxicity
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